The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: C. M. Dintsios, I. Beinhauer
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMC 2020-03-01
Sarja:Health Economics Review
Aiheet:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Linkit:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia